P320: 6-Thioguanine nucleotide levels are associated with trough levels of infliximab and adalimumab in Inflammatory Bowel Disease patients on combination therapy: A retrospective multicentre studyECCO'22Year: 2022
Authors: Yu, N.(1);Tassone, D.(1);Lee, T.(1);Phan, S.(2);Wu, D.M.(2);Tjahyadi, J.(3);Dutt, K.(3);Liou, H.(4);Wang, L.(5);Zhang, J.(6);Basnayake, C.(1,7);Wright, E.(1,7);Lust, M.(1);Niewiadomski, O.(1);Kamm, M.A.(1,7);Connell, W.(1);Thompson, A.(1,7);Hilmi, I.(8);Affendi Raja Ali, R.(9);Wei, S.C.(4);De Cruz, P.(2,7);van Langenberg, D.(3,10);Moore, G.T.(5,10);Friedman, A.B.(6);Ding, N.S.(1,7);
(1)St Vincent's Hospital Melbourne, Gastroenterology, Melbourne, Australia;(2)Austin Health, Gastroenterology, Melbourne, Australia;(3)Eastern Health, Gastroenterology, Melbourne, Australia;(4)National Taiwan University Hospital, Internal Medicine, Taipei, Taiwan;(5)Monash Health, Gastroenterology, Melbourne, Australia;(6)Alfred Health and Monash University, Gastroenterology, Melbourne, Australia;(7)University of Melbourne, Medicine, Melbourne, Australia;(8)University of Malaya Medical Centre, Medicine, Kuala Lumpur, Malaysia;(9)Universiti Kebangsaan Malaysia, Medicine, Kuala Lumpur, Malaysia;(10)Monash University, Medicine, Melbourne, Australia;COMBAT
P321: Mucosal Healing and Clinical remission after Treatment with Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA study): final results from a prospective, open-label, single-arm studyECCO'22Year: 2022
Authors: Wetwittayakhlang, P.(1);Golovics , P.(1);Hahn, G.(1);Bessissow, T.(1); Afif, W.(1);Wild, G.(1);Bitton, A.(1);LakatosPhD, P.L.(1);
(1)Mcgill University Health Center, IBD Centre, Montréal, Canada;IBD centre McGill University Health Centre
P322: Effectiveness of Tumor Necrosis Factor-alpha inhibitors and Thiopurines combination therapy according to 6-thioguanine nucleotides plasma levels: A Systematic Review.ECCO'22Year: 2022
Authors: Céspedes Martínez, E.(1);Robles, V.(1);Miarons, M.(2);Herrera-De Guise, C.(1);Mayorga-Ayala, L.(1);Perez, Z.(1);Oller, E.(1);Casellas, F.(1);Borruel, N.(1);
(1)Hospital Vall d'Hebron, Crohn's and colitis Attention Unit. Digestive System Research Unit., Barcelona, Spain;(2)Hospital Vall d'Hebron, Pharmacy Deparment- Hospital Vall d'Hebron Universitari Campus, Barcelona, Spain;
P323: The Crohn's Disease Exclusion Diet (CDED) for pouch inflammation: an interventional pilot studyECCO'22Year: 2022
Authors: Fliss Isakov, N.(1);Kornblum, J.(1);Zemel, M.(2);Hirsch, A.(1);Maharshak, N.(1);
(1)Tel Aviv Sourasky Medical Center, Department of Gastroenterology and Liver Diseases- Sackler Faculty of Medicine, Tel Aviv, Israel;(2)Tel Aviv Sourasky Medical Center, Surgery division, Tel Aviv, Israel;
P324: Tacrolimus for induction of remission in refractory ulcerative colitis: a Cochrane systematic reviewECCO'22Year: 2022
Authors: Gordon, M.(1);Sinopoulou, V.(1);Pana, M.(2);Moran, G.(2);
(1)UCLan, School of Medicine, Preston, United Kingdom;(2)University of Nottingham, Faculty of Medicine & Health Sciences, Nottingham, United Kingdom;
P325: Performance of new MRI scores: the modified Van Assche Index and the MAGNIFI-CD in the evaluation of the response to anti-TNFα in anoperineal fistulas in Crohn's diseaseECCO'22Year: 2022
Authors: Mtir, M.(1);Hassine, H.(1);Kahlaoui, F.(1);Cherif, D.(1);Tlili, R.(1);Kchir, H.(1);Maamouri, N.(1);
(1)La Rabta hospital, department of gastro-enterology B, Tunis, Tunisia;
P326: The effect of compliance during exclusive enteral nutrition on faecal calprotectin levels in children with Crohn’s diseaseECCO'22Year: 2022
Authors: Mckirdy, S.(1);Russell, R.(2);Hansen, R.(3);Svolos, V.(1);Gkikas, K.(1);Logan, M.(1);Gerasimidis, K.(1);
(1)University of Glasgow, Human Nutrition, Glasgow, United Kingdom;(2)Royal Hospital for Children and Young People, Department of Paediatric Gastroenterology, Edinburgh, United Kingdom;(3)Royal Hospital for Children, Department of Paediatric Gastroenterology, Glasgow, United Kingdom;
P327: Comparison of adalimumab drug levels and drug survival in proactive vs reactive therapeutic drug monitoringECCO'22Year: 2022
Authors: Shields, S.(1);Dunlop, A.(2);Barry, S.(3);Galloway, P.(2);Seenan, J.P.(1);Macdonald, J.(1);
(1)Queen Elizabeth University Hospital, Gastroenterology, Glasgow, United Kingdom;(2)Queen Elizabeth University Hospital, Biochemistry, Glasgow, United Kingdom;(3)University of Strathclyde, Department of Mathematics and Statistics, Glasgow, United Kingdom;
P328: In silico evaluation and pre-clinical efficacy of anti-TNF and anti-IL-23 combination therapy in Inflammatory Bowel DiseaseECCO'22Year: 2022
Authors: Perrigoue, J.(1);Muniz-Bongers, L.(1);Ong, L.(1);Chen, Y.(2);Chang, L.(2);Ngo, K.(2);Stojmirovic, A.(1);O’Brien, C.(1);Germinaro, M.(1);Rao, R.(1);Vetter, M.(1);Towne, J.(2);
(1)Janssen Research & Development- LLC, Immunology, Spring House, United States;(2)Janssen Research & Development- LLC, Immunology, San Diego, United States;VEGA
P329: Which should come first? Surgery or biologic therapy for ileocaecal Crohn’s disease in biologic naïve patientsECCO'22Year: 2022
Authors: Witjes, C.(1,2);Patel, A.(1,3);Zocche, D.(1);van 't Hullenaar- , C.(1);Cripps, S.(4);Travis, S.(5);George, B.(1);
(1)Oxford University Hospital- NHS Foundation Trust- Oxford, Department of Colorectal surgery, Oxford, United Kingdom;(2)Ijsselland Hospital, Department of General Surgery and Colorectal Surgery-, Capelle aan den IJssel, The Netherlands;(3)University hospital of Coventry and Warwickshire NHS Trust, Department of Colorectal surgery, Coventry, United Kingdom;(4)Oxford University Hospital- NHS Foundation Trust, Pharmacy Department – Gastroenterology/Hepatology, Oxford, United Kingdom;(5)Oxford University Hospital- NHS Foundation Trust, Translational Gastroenterology Unit, Oxford, United Kingdom;
P330: Immunity in patients with inflammatory bowel disease on biologic therapy after COVID 19 vaccinationECCO'22Year: 2022
Authors: Knezevic, T.(1);Cujic, D.(2);Odanovic, O.(1);Kralj, D.(1);Gnjatovic, M.(2);Kalaba, A.(1);Vrinic Kalem, D.(1);Svorcan, P.(1,3);Markovic, S.(1,3);
(1)University Hospital Zvezdara, Gastroenterology and hepatology, Belgrade, Serbia;(2)Institute for Application of Nuclear Energy, University of Belgrade, Belgrade, Serbia;(3)School of Medicine, University of Belgrade, Belgrade, Serbia;
P331: Composite outcomes in Crohn’s disease: a systematic review and meta-analysis of observational studiesECCO'22Year: 2022
Authors: Estevinho, M.M.(1);Sottomayor, C.(2);Alves, C.(3);Santago, M.(4);Ministro, P.(5);Lago, P.(6);Correia, L.(7);Gonçalves, R.(8);Carvalho, D.(9);Portela, F.(10);Dias, C.C.(11);Dignass, A.(12);Danese, S.(13);Peyrin-Biroulet, L.(14);Magro, F.(15);
(1)Centro Hospitalar Vila Nova de Gaia/Espinho, Department of Gastroenterology, Vila Nova de Gaia, Portugal;(2)Unit of Pharmacology and Therapeutics- Faculty of Medicine- University of Porto, Department of Biomedicine-, Porto, Portugal;(3)Unit of Pharmacology and Therapeutics- Faculty of Medicine- University of Porto, Department of Biomedicine, Porto, Portugal;(4)Center for Health Technology and Services Research CINTESIS, Biomedicine, Porto, Portugal;(5)Centro Hospitalar Tondela-Viseu, Department of Gastroenterology, Viseu, Portugal;(6)Porto Hospital Center- Hospital de Santo António, Department of Gastroenterology, Porto, Portugal;(7)Lisbon North Hospital Centre- Santa Maria Hospital, Department of Gastroenterology, Lisbon, Portugal;(8)Hospital de Braga, Department of Gastroenterology, Braga, Portugal;(9)Santo António dos Capuchos Hospital at Centro Hospitalar Lisboa Central, Department of Gastroenterology, Lisbon, Portugal;(10)University Hospital Centre of Coimbra, Department of Gastroenterology, Coimbra, Portugal;(11)Information and Health Decision Sciences- Faculty of Medicine- University of Porto, Department of Community Medicine, Porto, Portugal;(12)Agaplesion Markus Hospital- Dept. of Medicine I, Gastroenterology, Frankfurt, Germany;(13)Humanitas Clinical and Research Center IRCCS, Inflammatory Bowel Disease IBD Center- Department of Gastroenterology-, Milan, Italy;(14)University Hospital of Nancy- University of Lorraine, Department of Gastroenterology and Inserm NGERE U1256-, Vandoeuvre-lès-Nancy, France;(15)São João University Hospital Center CHUSJ, epartment of Gastroenterology, Porto, Portugal;GEDII - Portuguese IBD Group
P332: Group-based Acceptance and Commitment Therapy (ACT) is acceptable and effective at reducing psychological distress in patients with Inflammatory Bowel Disease (IBD).ECCO'22Year: 2022
Authors: Duff, A.(1);De Petrillo, A.(2);Reynolds, D.(3);Bangura, E.(4);Pavilidis, P.(1);Mawdsley, J.(1);
(1)Guy's and St. Thomas hospital- London, Gastroenterology, London, United Kingdom;(2)King's College Hospital- London, Pediatrics, London, United Kingdom;(3)Guy's and St. Thomas hospital- London, Pediatrics, London, United Kingdom;(4)Kings College, Clinical Psychology, London, United Kingdom;
P333: Precise and unbiased infliximab dosing in patients with inflammatory bowel diseases using a multi-model averaging approachECCO'22Year: 2022
Authors: Kantasiripitak, W.(1);Outtier, A.(2,3);Thomas, D.(1);Kensert, A.(1);Wang, Z.(1);Sabino, J.(2,3);Wicha, S.G.(4);Vermeire, S.(2,3);Ferrante, M.(2,3);Dreesen, E.(1);
(1)University of Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium;(2)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(3)University of Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium;(4)University of Hamburg, Department of Clinical Pharmacy, Hamburg, Germany;
P334: Effectiveness and safety of ustekinumab in Crohn’s disease: short and long-term results of a multi-refractory cohort.ECCO'22Year: 2022
Authors: Aparicio-Serrano, A.(1);Zamora Olaya, J.M.(1);Ortiz Chimbo, D.S.(1);Rodríguez Tirado, M.I.(1);Gómez Pérez, A.(1);Soto Escribano, P.(1);Marín Pedrosa, S.(1);Iglesias Flores, E.(1);Benítez, J.M.(1);
(1)Reina Sofía University Hospital, Gastroenterology and Hepatology, Córdoba, Spain;
P335: Utility of Intestinal Ultrasound in Monitoring Disease Activity in Ulcerative Colitis Patients Treated with BiologicsECCO'22Year: 2022
Authors: Tomašić, V.(1);Kralj, D.(1);Bišćanin, A.(1);Ćaćić, P.(1);Ogresta, D.(1);Dorosulić, Z.(1);Hrabar, D.(1);
(1)University Hospital Centre Sestre milosrdnice, Department of Gastroenterology and Hepatology, Zagreb, Croatia;
P336: Can Mesenchymal Stem Cell (MSC) apoptosis be used as a biomarker for treatment success in perianal fistulising Crohn’s Disease (pCD)? Findings from a prospective pilot studyECCO'22Year: 2022
Authors: Iqbal, N.(1,2);Constable, L.(3,4);Tozer, P.(1,2);Lung, P.(1);Hart, A.(1,4);Powell, N.(4);
(1)St Mark's Hospital, Robin Phillips Fistula Research Unit, London, United Kingdom;(2)Imperial College London, Department of Surgery and Cancer, London, United Kingdom;(3)Kings College London, Department of Inflammation Biology- School of Immunology and Microbial Science, London, United Kingdom;(4)Imperial College London, Department of Metabolism- Digestion and Reproduction, London, United Kingdom;
P338: Early proactive drug monitoring strategy of infliximab as monotherapy for inflammatory bowel disease in paediatric patients is associated with good sustained clinical remissionECCO'22Year: 2022
Authors: Girard, C.(1);Achkar, S.(2);Sassine, S.(2);Chapuy, L.(3);Jantchou, P.(1);Deslandres, C.(1);
(1)CHU Sainte-Justine- Université de Montréal, Department of Pediatrics. Division of Gastroenterology-Hepatology and Nutrition, Montreal, Canada;(2)Université de Montréal, Faculty of medecine, Montreal, Canada;(3)Montreal Children’s Hospital- McGill University, Department of Pediatrics. Division of Gastroenterology- Hepatology- and Nutrition., Montreal, Canada;
P339: Effect of antinuclear antibodies on pharmacokinetics of anti-TNF therapy in patients with Inflammatory Bowel DiseaseECCO'22Year: 2022
Authors: TheodorakiMD- MA- PhD c, E.(1);Orfanoudaki, E.(1);Foteinogiannopoulou, K.(1);Andreou, N.P.(2);Gazouli, M.(2);Koutroubakis, I.(1);
(1)University Hospital of Heraklion- School of Medicine, Department of Gastroenterology, Heraklion, Greece;(2)Laboratory of Biology- School of Medicine- National and Kapodistrian University of Athens, Department of Basic Medical Sciences, Anthens, Greece;
